Japanese Encephalitis Medication
- Author: Antonette B Climaco, MD; Chief Editor: Burke A Cunha, MD more...
No effective antiviral exists.
As stated above, mannitol is used to decrease intracranial pressure, when needed.
There are 4 classes of Japanese encephalitis vaccines. Ixiaro is the Japanese encephalitis vaccine available in the United States.
Mannitol is recommended by some experts to help reduce intracranial pressure. Mannitol induces diuresis, which increases serum osmotic concentration. In the brain, this causes water to flow from brain cells into vascular space, thereby decreasing intracranial pressure.
Mannitol may be used to decrease intracranial pressure. It may reduce subarachnoid space pressure by creating an osmotic gradient between CSF in the arachnoid space and plasma. This agent is not for long-term use.
Induction of the antibody response to vaccine provides the capability to neutralize live Japanese encephalitis virus (JEV).
Ixiaro is an inactivated vaccine prepared by propagating Japanese encephalitis virus strain SA14-14-2 in Vero cells. It is available in prefilled, single-dose syringes without preservatives or thimerosal. Antibody response is measured with a 50% plaque-reduction neutralization antibody test; a threshold of 1:10 or higher is considered protective immunity.
It is the only currently available Japanese encephalitis vaccine in the United States.
Takhampunya R, Kim HC, Tippayachai B, Kengluecha A, Klein TA, Lee WJ, et al. Emergence of Japanese encephalitis virus genotype V in the Republic of Korea. Virol J. 2011 Sep 23. 8:449:[Medline]. [Full Text].
Unni SK, Ružek D, Chhatbar C, Mishra R, Johri MK, Singh SK. Japanese encephalitis virus: from genome to infectome. Microbes Infect. 2011 Apr. 13(4):312-21. [Medline].
Thongtan T, Cheepsunthorn P, Chaiworakul V, Rattanarungsan C, Wikan N, Smith DR. Highly permissive infection of microglial cells by Japanese encephalitis virus: a possible role as a viral reservoir. Microbes Infect. 2010 Jan. 12(1):37-45. [Medline].
Shukla V, Shakya AK, Shukla M, Kumari N, Krishnani N, Dhole TN, et al. Circulating levels of matrix metalloproteinases and tissue inhibitors of matrix metalloproteinases during Japanese encephalitis virus infection. Virusdisease. 2016 Mar. 27(1):63-76. [Medline].
Hills SL, Stoltey J, Martinez D, Kim P, Sheriff H, Zangeneh A, et al. Journal of Travel Medicine. 2014 Sep-Oct. 21(5):310-313. [Full Text].
Campbell GL, Hills SL, Fischer M, Jacobson JA, Hoke CH, Hombach JM, et al. Estimated global incidence of Japanese encephalitis: a systematic review. Bull World Health Organ. 2011 Oct 1. 89(10):766-74E. [Medline]. [Full Text].
Hanna JN, Ritchie SA, Phillips DA, Shield J, Bailey MC, Mackenzie JS, et al. An outbreak of Japanese encephalitis in the Torres Strait, Australia, 1995. Med J Aust. 1996 Sep 2. 165(5):256-60. [Medline].
Baylis M, Barker CM, Caminade C, Joshi BR, Pant GR, Rayamajhi A, et al. Emergence or improved detection of Japanese encephalitis virus in the Himalayan highlands?. Trans R Soc Trop Med Hyg. 2016 Apr. 110(4):209-11. [Medline]. [Full Text].
Kumar R, Tripathi P, Singh S, Bannerji G. Clinical features in children hospitalized during the 2005 epidemic of Japanese encephalitis in Uttar Pradesh, India. Clin Infect Dis. 2006 Jul 15. 43(2):123-31. [Medline].
Li X, Cui S, Gao X, Wang H, Song M, Li M, et al. The Spatio-temporal Distribution of Japanese Encephalitis Cases in Different Age Groups in Mainland China, 2004 - 2014. PLoS Negl Trop Dis. 2016 Apr 6. 10(4):[Medline]. [Full Text].
WHO. Japanese Encephalitis Vaccines: WHO position paper, February 2015 - Recommendations. Vaccine. 2016 Jan 12. 34(3):302-3. [Medline].
Sarkari NB, Thacker AK, Barthwal SP, Mishra VK, Prapann S, Srivastava D, et al. Japanese encephalitis (JE) part II: 14 years' follow-up of survivors. J Neurol. 2012 Jan. 259 (1):58-69. [Medline].
Richman DD, Whitley RJ, Hayden FG. Clinical Virology. New York, NY: Churchill Livingstone; 1997.
Bandyopadhyay D, Ganesan V, Choudhury C, Kar SS, Karmakar P, Choudhary V, et al. Two Uncommon Causes of Guillain-Barré Syndrome: Hepatitis E and Japanese Encephalitis. Case Rep Neurol Med. 2015. 2015:[Medline]. [Full Text].
Handique SK, Das RR, Saharia B, Das P, Buragohain R, Saikia P. Coinfection of Japanese encephalitis with neurocysticercosis: an imaging study. AJNR Am J Neuroradiol. 2008 Jan. 29(1):170-5. [Medline]. [Full Text].
Verma R, Praharaj HN, Patil TB, Giri P. Acute transverse myelitis following Japanese encephalitis viral infection: an uncommon complication of a common disease. BMJ Case Rep. 2012 Sep 24. 2012:[Medline].
Solomon T, Thao LT, Dung NM, Kneen R, Hung NT, Nisalak A, et al. Rapid diagnosis of Japanese encephalitis by using an immunoglobulin M dot enzyme immunoassay. J Clin Microbiol. 1998 Jul. 36(7):2030-4. [Medline]. [Full Text].
Hoke CH Jr, Vaughn DW, Nisalak A, Intralawan P, Poolsuppasit S, Jongsawas V, et al. Effect of high-dose dexamethasone on the outcome of acute encephalitis due to Japanese encephalitis virus. J Infect Dis. 1992 Apr. 165(4):631-7. [Medline].
Harinasuta C, Nimmanitya S, Titsyakorn U. The effect of interferon-alpha A on two cases of Japanese encephalitis in Thailand. Southeast Asian J Trop Med Public Health. 1985 Jun. 16(2):332-6. [Medline].
Solomon T, Dung NM, Wills B, Kneen R, Gainsborough M, Diet TV, et al. Interferon alfa-2a in Japanese encephalitis: a randomised double-blind placebo-controlled trial. Lancet. 2003 Mar 8. 361(9360):821-6. [Medline].
Rayamajhi A, Nightingale S, Bhatta NK, Singh R, Kneen R, Ledger E, et al. A preliminary randomized double blind placebo-controlled trial of intravenous immunoglobulin for Japanese encephalitis in Nepal. PLoS One. 2015 Apr 17. 10(4):[Medline]. [Full Text].
Lee E, Pavy M, Young N, Freeman C, Lobigs M. Antiviral effect of the heparan sulfate mimetic, PI-88, against dengue and encephalitic flaviviruses. Antiviral Res. 2006 Jan. 69(1):31-8. [Medline].
Saxena SK, Mathur A, Srivastava RC. Inhibition of Japanese encephalitis virus infection by diethyldithiocarbamate is independent of its antioxidant potential. Antivir Chem Chemother. 2003 Mar. 14(2):91-8. [Medline].
Swarup V, Ghosh J, Mishra MK, Basu A. Novel strategy for treatment of Japanese encephalitis using arctigenin, a plant lignan. J Antimicrob Chemother. 2008 Mar. 61(3):679-88. [Medline].
Mishra MK, Basu A. Minocycline neuroprotects, reduces microglial activation, inhibits caspase 3 induction, and viral replication following Japanese encephalitis. J Neurochem. 2008 Jun. 105(5):1582-95. [Medline]. [Full Text].
Kumar R, Basu A, Sinha S, Das M, Tripathi P, Jain A, et al. Role of oral Minocycline in acute encephalitis syndrome in India - a randomized controlled trial. BMC Infect Dis. 2016 Feb 4. 16(1):67. [Medline]. [Full Text].
Topno R, Khan SA, Chowdhury P, Mahanta J. Pharmacodynamics of aminoglycosides and tetracycline derivatives against Japanese encephalitis virus. Asian Pac J Trop Med. 2016 Mar. 9(3):241-6. [Medline]. [Full Text].
Lowry F. Traveling Children Should Get Japanese Encephalitis Vaccine. Medscape Medical News. Jun 19 2013. Available at http://www.medscape.com/viewarticle/806601. Accessed: Jun 26 2013.
Harakuni T, Kohama H, Tadano M, et al. Mucosal vaccination approach against mosquito-borne Japanese encephalitis virus. Jpn J Infect Dis. 2009 Jan. 62(1):37-45. [Medline].
Schiøler KL, Samuel M, Wai KL. Vaccines for preventing Japanese encephalitis. Cochrane Database Syst Rev. 2007 Jul 18. CD004263. [Medline].
Yang SE, Pan MJ, Tseng HF, Liau MY. The efficacy of mouse-brain inactivated Nakayama strain Japanese encephalitis vaccine--results from 30 years experience in Taiwan. Vaccine. 2006 Mar 24. 24(14):2669-73. [Medline].
Connor BA, Bunn WB. The Changing Risk of Japanese Encephalitis for Business Travelers. Workplace Health Saf. 2015 Dec. 63 (12):568. [Medline].
Ravi V, Taly AB, Shankar SK, Shenoy PK, Desai A, Nagaraja D, et al. Association of Japanese encephalitis virus infection with Guillain-Barré syndrome in endemic areas of south India. Acta Neurol Scand. 1994 Jul. 90(1):67-72. [Medline].
Kuwayama M, Ito M, Takao S, Shimazu Y, Fukuda S, Miyazaki K, et al. Japanese encephalitis virus in meningitis patients, Japan. Emerg Infect Dis. 2005 Mar. 11(3):471-3. [Medline].
Chokephaibulkit K, Houillon G, Feroldi E, Bouckenooghe A. Safety and immunogenicity of live attenuated Japanese encephalitis chimeric virus vaccine (Imojev®) in children. Expert Rev Vaccines. 2015 Nov 20. [Medline].
Solomon T, Thao TT, Lewthwaite P, Ooi MH, Kneen R, Dung NM, et al. A cohort study to assess the new WHO Japanese encephalitis surveillance standards. Bull World Health Organ. 2008 Mar. 86(3):178-86. [Medline]. [Full Text].
Fischer M, Lindsey N, Staples JE, Hills S; Centers for Disease Control and Prevention (CDC). Japanese encephalitis vaccines: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. 2010 May 12. 59:1-27. [Medline]. [Full Text].
Dwibedi B, Mohapatra N, Rathore SK, Panda M, Pati SS, Sabat J, et al. An outbreak of Japanese encephalitis after two decades in Odisha, India. Indian J Med Res. 2015 Dec. 142 Suppl:S30-2. [Medline]. [Full Text].
Centers for Disease Control and Prevention. CDC Health Information For International Travel 2016. New York: Oxford University Press; 2016.
Burke DS, Nisalak A, Ussery MA, Laorakpongse T, Chantavibul S. Kinetics of IgM and IgG responses to Japanese encephalitis virus in human serum and cerebrospinal fluid. J Infect Dis. 1985 Jun. 151(6):1093-9. [Medline].